BR112014017788A2 - proteína de fusão de interferona e de seção fc de imunoglobulina - Google Patents

proteína de fusão de interferona e de seção fc de imunoglobulina

Info

Publication number
BR112014017788A2
BR112014017788A2 BR112014017788A BR112014017788A BR112014017788A2 BR 112014017788 A2 BR112014017788 A2 BR 112014017788A2 BR 112014017788 A BR112014017788 A BR 112014017788A BR 112014017788 A BR112014017788 A BR 112014017788A BR 112014017788 A2 BR112014017788 A2 BR 112014017788A2
Authority
BR
Brazil
Prior art keywords
immunoglobulin
section
fusion protein
interferon fusion
interferon
Prior art date
Application number
BR112014017788A
Other languages
English (en)
Portuguese (pt)
Inventor
Chin Wu Chung
Ting Chen Han
Yung Kuo Tsun
Original Assignee
Sbc Virbac Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbc Virbac Biotech Co Ltd filed Critical Sbc Virbac Biotech Co Ltd
Publication of BR112014017788A2 publication Critical patent/BR112014017788A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112014017788A 2012-01-19 2013-01-18 proteína de fusão de interferona e de seção fc de imunoglobulina BR112014017788A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210016618 2012-01-19
PCT/CN2013/070693 WO2013107388A1 (zh) 2012-01-19 2013-01-18 干扰素和免疫球蛋白Fc段的融合蛋白

Publications (1)

Publication Number Publication Date
BR112014017788A2 true BR112014017788A2 (pt) 2017-06-27

Family

ID=48798651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017788A BR112014017788A2 (pt) 2012-01-19 2013-01-18 proteína de fusão de interferona e de seção fc de imunoglobulina

Country Status (5)

Country Link
KR (1) KR20150002588A (zh)
CN (2) CN105001340A (zh)
BR (1) BR112014017788A2 (zh)
PH (1) PH12014501643A1 (zh)
WO (1) WO2013107388A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292337A (zh) * 2013-07-17 2015-01-21 施怀哲维克生物科技股份有限公司 猪融合干扰素
CN110055272A (zh) * 2019-04-18 2019-07-26 西北农林科技大学 一种抑制prrs病毒增殖的靶向抗体治疗剂
CN113717270A (zh) * 2020-05-26 2021-11-30 成都彤琦恩生物科技有限公司 一种猪干扰素-α8突变体及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CN101967196A (zh) * 2010-11-10 2011-02-09 夏志南 一种干扰素融合蛋白及其制备和应用

Also Published As

Publication number Publication date
WO2013107388A1 (zh) 2013-07-25
PH12014501643A1 (en) 2014-10-13
KR20150002588A (ko) 2015-01-07
CN103214579B (zh) 2015-08-26
CN103214579A (zh) 2013-07-24
CN105001340A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
MA46534A (fr) Protéines de fusion fc hétérodimères il15/il15r
HK1208827A1 (zh) 白介素- 融合蛋白及其用途
HK1208476A1 (zh) 抗體、融合蛋白，及它們的使用方法
UY34017A (es) Proteínas de fusión y vacunas de combinación
EP3019531A4 (en) Immunoglobulin fusion proteins and compositions thereof
CL2014003605A1 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
BR112015003838A2 (pt) formulações de anticorpo e proteína
DK2940135T3 (da) Heterodimeriseret polypeptid
CO7020851A2 (es) Proteínas y péptidos modificados
BR112014019825A2 (pt) Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
EP2723380A4 (en) HYBRID LIGHT CHAIN IMMUNOGLOBULIN PROTEINS AND METHODS OF USE THEREOF
EP2968551A4 (en) FUSION PROTEINS AND METHOD THEREFOR
CL2016000219A1 (es) Proteinas de fusión terapéutica.
EP2975052A4 (en) Epitope of rsv fusion protein and antibody identifying same
EP3049445A4 (en) Interleukin-2 fusion proteins and uses thereof
EP3000825A4 (en) Trans-tumoral peptide specific to neuropilin and fusion protein having same peptide fused therein
HRP20190434T1 (hr) Fuzijski protein
DK3434760T3 (da) Fremgangsmåder til forøgelse af mannose-indholdet i rekombinante proteiner
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
BR112015009462A2 (pt) composição farmacêutica estável do tnfr:fc proteína de fusão
EP2969009A4 (en) MODIFIED FC FUSION PROTEINS
EP2930189A4 (en) CHEMOKINE-CYTOKINE FUSION PROTEIN AND USE THEREOF

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Ipc: C07K 19/00 (2006.01), C12N 15/62 (2006.01), C12N 1

B07E Notice of approval relating to section 229 industrial property law
B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements